業界コンテキスト
GeneDx Holdings Corp [WGS]
ピボットデータ
ピボット統計
| 指標 | 平均 | 中央値 | 標準偏差 |
|---|---|---|---|
| 上昇 % | 17.13% | 17.13% | 0.00% |
| 下落 % | -50.58% | -50.58% | 0.00% |
| 期間 | 12.5d | 13d | 0.7d |
| 検出ピボット合計 | 3 |
| 上昇/下落区間 | 2 (1 上昇 / 1 下落) |
| 直近ピボット | Bottom @ $34.51 日付 2026-05-05 |
| 直近ピボットからの変化 | $23.57 (68.30%) |
次のピボット予測 直近: $63.54
| 予測される次のタイプ | Top |
| 予測価格(平均) | $40.42 |
| 予測価格(中央値) | $40.42 |
| 予測価格レンジ (~68%) | $40.42 - $40.42 |
| 平均目標までの変化 | $-23.12 (-36.39%) |
| 予測日(平均) | 2026-05-17 |
| 予測日レンジ (~68%) | 2026-05-16 - 2026-05-18 |
| 根拠 | Based on 1 historical gains (Avg: 17.13%, Median: 17.13%, StdDev: 0.00%) and duration (Avg: 12.5 days, StdDev: 0.7 days) |
| 注記 | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
GeneDx Holdings Corp climbs 4.80%.
GeneDx Holdings Corp (WGS) stock price showed an impressive upswing on Tuesday after the stock rose $2.66 (4.80%) from the previous session on normal volume. Showing significant relative strength, the stock rose today while the NASDAQ fell -0.43%. A total of 1.01M stocks were traded yesterday, valued at $58.70M, 5 321 shares more than the previous day (1 005 424 shares traded). This is near the average volume for the stock at 1.12M shares traded per day.
GeneDx Holdings Corp signals
There is no conclusive signals given from RSI. The price is above the short-term average yet below the long-term average, with the short-term average still below the long-term average; signals are mixed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (3.3%), medium- (3.3%), and long-term (3.3%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
GeneDx Holdings Corp Support & Resistance Levels
The stock is approaching the closest resistance level at $62.30. approximately $4.22 (7.27%) away. Approaching it. Breaking above this level could signal further upside where next resistance level will be found at $66.9. On a fall back there will be support at $40.5 The dis das resistance s140.5 -
GeneDx Holdings Corp Evaluation
- 短期 スコア: 1.02
- 中期 スコア: -0.29
- 長期 スコア: -0.56
インサイダー動向
GetAGraph InsiderPower
関係マップ
相関スナップショット
<span style="background-color: lightcoral">Overvalued: <i class="arrow arrow-down"></i>0.63% <strong>$63.98</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-10-27 | - | - | - | - |
| Q2/2025 | 2025-07-29 | - | $0.0900 | - | - |
| Q1/2025 | 2025-04-30 | $0.280 | $0.110 | 154.55% | 87.12M |
| Q4/2024 | 2025-02-18 | $0.700 | $0.0400 | 1 650.00% | 95.64M |
| Q3/2024 | 2024-10-29 | $0.0400 | $-0.190 | 121.05% | 76.87M |
| Q2/2024 | 2024-07-30 | $-0.110 | $-0.260 | 57.69% | 70.51M |
| ~2024 Q1? | 2024-04-29 | $-0.330 | $-0.680 | 51.47% | 62.42M |
| ~2023 Q4? | 2024-02-20 | $-0.590 | $-0.600 | 1.67% | 57.42M |
Analyst view
Analyst targets
News flow
Latest company news
Market coverage
globenewswire.com GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition – Hagens Berman Jun 24, 2026 prnewswire.com Robbins LLP Urges WGS Stockholders Who Lost Money Investing in GeneDx Holdings Corp. to Contact the Firm for Information About Leading the Class Action Jun 24, 2026 newsfilecorp.com GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC Jun 24, 2026 feeds.newsfilecorp.com WGS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026 Jun 24, 2026Company releases
Company context
Company profile
GeneDx Holdings Corp functions as a health intelligence firm singularly focused on the individual patient It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities These sophisticated algorithms are applied to vast longitudinal clinical and genomic datasets to construct comprehensive dynamic models of human health ultimately defining personalized optimal pathways for each persons wellbeing Through its exclusive Centrellis health intelligence platform the company gains profound insights into both disease states and overall wellness enabling it to furnish evidencebased solutions for the most critical medical challenges Eric Schadt established the corporation in October 2015 and its principal offices are located in Stamford Connecticut
Navigation